Meditech snares Moses for board
Thursday, 30 May, 2002
Hyaluron drug delivery company Meditech Research (ASX:MTR) has named sought-after business analyst Bob Moses as chairman of its board.
Moses joined the board in October last year after retiring as vice-president of CSL.
His appointment to the chairman's position sees him replace acting chairman Prof Richard Fox, a Royal Melbourne Hospital oncologist who will remain on the board and continue to lead the company's clinical trail activities.
Fox said Moses would bring to the company 35 years of experience in the pharmaceutical and biotech industry.
"His commercial understanding greatly strengthens the company at a time when its technology is emerging from the laboratory and attracting the attention of multinational pharmaceutical companies," Fox said.
It has been a busy couple of weeks for Moses who last week was named a non-executive director on the board of Amrad Corporation as part of a compromise between the company and its major shareholder Circadian Technologies.
Moses is also the chairman of Circadian subsidiary Antisense Therapeutics.
Before joining CSL, Moses spent 17 years in a variety of management roles within multinational pharmaceutical house, Eli Lilly.
The appointment comes a week after the Perth-based company signed a licence agreement with the Lion's Eye Institute allowing the institute to use Meditech's patents in the development of products for the treatment and prevention of eye diseases.
The patents relate to the use of hyaluronic acid as a transporter of DNA into cells.
Also this month, the company completed Phase I trials of its anti-cancer therapy HyDox, finding the treatment was safe for patients with breast cancer, renal carcinoma, sarcoma and prostate cancer.
The trials, headed by Fox, were conducted through the Centre For Developmental Cancer Therapeutics (CDCT), a Melbourne consortium comprising The Royal Melbourne Hospital, The Walter & Eliza Hall Institute, The Peter MacCallum Cancer Institute, The Ludwig Institute, The Austin and Repatriation Medical Centre, and Western Hospital.
Plug-and-play test evaluates T cell immunotherapy effectiveness
The plug-and-play test enables real-time monitoring of T cells that have been engineered to fight...
Common heart medicine may be causing depression
Beta blockers are unlikely to be needed for heart attack patients who have a normal pumping...
CRISPR molecular scissors can introduce genetic defects
CRISPR molecular scissors have the potential to revolutionise the treatment of genetic diseases,...
